Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ101 in advanced solid tumors
NCT07181473Phase 1Recruiting
- Sponsor
- Phrontline Biopharma
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of eftansomatropin alfa in lung cancer, prostate cancer (PCa), esophageal cancer and 1 more, sponsored by Phrontline Biopharma. Primary endpoints: Dose-limiting toxicities at 21 days, Serious Adverse Events at 2 years and 2 more. Started Aug 2025; status: recruiting.
02
Drugs
eftansomatropin alfa
03
Conditions
lung cancerprostate cancer (PCa)esophageal cancerSolid tumor malignancy
Beyond the preview
Go deeper on NCT07181473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07181473.